RANI

Rani Therapeutics Holdings, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1856725Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$2.0M

Net Income FY2025

$(30.0M)

EPS (Basic, as reported)

$-0.45

Net Margin FY2025

-1817.1%

ROE FY2025

-89.9%

Total Equity

$33.0M

Shares Out

—

Business description

Rani Therapeutics Holdings, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 2

Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025

Revenue030012

Research & development(12)(26)(37)(40)(27)(20)

General & administrative(5)(28)(27)(26)(24)(20)

Total operating expenses(17)(54)(63)(66)(54)(40)

Operating income(17)(52)(63)(66)(53)(38)

Interest expense00(1)(5)(5)(3)

Interest & investment income00————

Pre-tax income(17)(53)(63)(68)——

Income tax expense000000

Net income(17)(8)(31)(34)(30)(30)

EPS — basic—($0.43)———($0.45)

EPS — diluted—($0.43)———($0.45)

Shares outstanding — basic (M)—00000

Shares outstanding — diluted (M)—00000

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.